Migraine prophylactic drugs – something new under the sun?

Bibliography

• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):1-150
   Google Scholar
• Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010;11:289-99
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Hagen K, Jensen R. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jonsson B, Wittchen HU, Cost of disorders of the brain in Europe. Eur J Neurol 2005;12:1-27
   PubMed Web of Science ®Google Scholar
• Silberstein SD. For the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62
   PubMed Web of Science ®Google Scholar
• Manack A, Buse DC, Serrano D, Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology 2011;76:711-18
   PubMed Web of Science ®Google Scholar
• Alstadhaug KB. Migraine and the hypothalamus. Cephalalgia 2009;29:809-17
   PubMed Web of Science ®Google Scholar
• Levy D. Migraine pain and nociceptor activation – where do we stand? Headache 2010;50:909-16
   PubMed Web of Science ®Google Scholar
• Lambert GA. The lack of peripheral pathology in migraine headache. Headache 2010;50:895-908
   PubMed Web of Science ®Google Scholar
• Zanchin G, Dainese F, Trucco M, Osmophobia in migraine and tension-type headache and its clinical features in patients with migraine. Cephalalgia 2007;27:1061-8
   PubMed Web of Science ®Google Scholar
• Vingen JV, Pareja JA, Støren O, Phophobia in migraine. Cephalalgia 1998;18:243-9
   PubMed Web of Science ®Google Scholar
• Denuelle M, Boulloche N, Payoux P, A PET study of photophobia during spontaneous migraine attacks. Neurology 2011;76:213-18
   PubMed Web of Science ®Google Scholar
• Doepp F, Schreiber SJ, Dreier JP, Migraine aggravation caused by cephalic venous congestion. Headache 2003;43:96-8
   PubMed Web of Science ®Google Scholar
• Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 2007;27:1429-39
   Web of Science ®Google Scholar
• Kurosawa M, Messlinger K, Pawlak M, Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 1995;114:1397-402
   PubMed Web of Science ®Google Scholar
• Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-56
   Google Scholar
• Wolff HG, Tunis MM, Goodell H. Studies on headache: Evidence of tissue damage and changes in pain sensitivity in subjects with vascular headaches of the migraine type. Trans Assoc Am Physicians 1954;13:229
   Google Scholar
• Thalakoti S, Patil VV, Damodaram S, Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007;47:1008-23
   PubMed Web of Science ®Google Scholar
• Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;12:560-4
   Web of Science ®Google Scholar
• Kristiansen KA, Edvinsson L. Neurogenic inflammation: a study of rat trigeminal ganglion. J Headache Pain 2010;11:485-95
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
   PubMed Web of Science ®Google Scholar
• Somjen GG. Mechanisms for spreading depression and hypoxic spreading-like depolarization. Physiol Rev 2001;81:1065-96
   PubMed Web of Science ®Google Scholar
• Wessman M, Terwindt GM, Kaunisto MA, Migraine: a complex genetic disorder. Lancet Neurol 2007;6:521-32
   PubMed Web of Science ®Google Scholar
• Kong LL, Yu LC. Involvement of mu- and delta-opioid receptors in the antinociceptive effects induced by AMPA receptor antagonist in the spinal cord of rats. Neurosci Lett 2006;402:180-3
   PubMed Web of Science ®Google Scholar
• Kuner R. Central mechanisms of pathological pain. Nat Med 2010;16:1258-66
   PubMed Web of Science ®Google Scholar
• Burstein R, Cutrer MF Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000;123:1703-9
   PubMed Web of Science ®Google Scholar
• Sanchez Del Rio M, Linera JA. Functional neuroimaging in headaches. Lancet Neurol 2004;3:645-51
   PubMed Web of Science ®Google Scholar
• Welch KMA. Contemporary concepts of migraine pathogenesis. Neurology 2003;61(Suppl 4):S2-8
   PubMed Web of Science ®Google Scholar
• Blau JN. Migraine: theories of pathogenesis. Lancet 1992;339:1202-7
   PubMed Web of Science ®Google Scholar
• Copola G, pierelli F, Schoenen J. Habituation and migraine. Neurol Learn Mem 2009;92:249-59
   PubMed Web of Science ®Google Scholar
• Noseda R, Kainz V, Jakubowski M, A neuronal mechanism for exacerbation of headache by light. Nat Neurosci 2010;13:239-45
   PubMed Web of Science ®Google Scholar
• Alstadhaug KB. Periodicity of migraine. In: Clarke LB. editor. Migraine disorders research trends. Nova Science; New York: 2007. p. 107-44
   Google Scholar
• Hattar S, Lucas RJ, Mroskovsky N, Melanopsin and rod-cone photoreceptive system account for all major accessory visual functions in mice. Nature 2003;424:76-81
   PubMed Web of Science ®Google Scholar
• Gooley JJ, Lu J, Fisher D, Saper CB. A broad role of melanopsin in nonvisual photoreception. J Neurosci 2003;23:7093-06
   PubMed Web of Science ®Google Scholar
• Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972;22:355-65
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Sances G, Borella P, Magnesium prophylaxis of menstrual migraine. Effects on intracellular magnesium. Headache 1996;31:298-301
   Web of Science ®Google Scholar
• Mauskop A. Editorial: evidence linking magnesium deficiency to migraines. Cephalalgia 1999;19:766-7
   PubMed Web of Science ®Google Scholar
• Sparaco M, Feleppa M, Lipton RB, Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 2005;26:361-72
   Web of Science ®Google Scholar
• MacGregor EA, Brandes JL, Silberstein S, Safety and tolerability of short-term preventive frovatriptan: a combined analyses. Headache 2009;49:1298-14
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Csanyi A, Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009;29:742-50
   PubMedGoogle Scholar
• Hauge AW, Asghar MS. Schytz, et al. Effects of tonabersat on migraine with aura: a randomised double-blind, placebo-controlled crossover study. Lancet Neurol 2009;8:718-23
   PubMed Web of Science ®Google Scholar
• Cady RK, Mathew N, Diener HC, Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216-26
   PubMed Web of Science ®Google Scholar
• Chankrachang S, Arayawichanunt A, Poungvarin N, Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. Headache 2011;51:52-63
   PubMed Web of Science ®Google Scholar
• Couch JR. Amitriptyline versus placebo study group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Berner T, Tobin J, Scheduled short-term prevention with frovatriptan for migraine occuring exclusively in association with menstruation. Headache 2009;49:1283-97
   PubMed Web of Science ®Google Scholar
• Alstahaug KB, Odeh F, Salvesen R, Bekkelund S. Prophylaxis of migraine with melatonin. A randomized controlled trial. Neurology 2010;75:1527-32
   PubMed Web of Science ®Google Scholar
• Tronvik E, Stovner LJ, Helde G, Prophylactic treatment of migraine with an angiotensin II receptor blocker. A randomized controlled trial. JAMA 2003;289:65-9
   PubMed Web of Science ®Google Scholar
• Mulleneers WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalgia 2008;28:585-97
   PubMed Web of Science ®Google Scholar
• Mathew NT, Saper JR, Silberstein SD, Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalagia 1997;17:103-8
   PubMed Web of Science ®Google Scholar
• Freitag FG, Collins SD, Carlson HA, A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;458:1652-9
   Google Scholar
• Brandes JL, Saper JR, Diamond M, Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Neeto W, Schmitt J, Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61:490-5
   PubMed Web of Science ®Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlof C, Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943-50
   PubMed Web of Science ®Google Scholar
• Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 2010;24:21-33
   PubMed Web of Science ®Google Scholar
• Gode S, Celebisoy N, Karazli T, Clinical assessment of topiramate therapy in patients with migrainous vertigo. Headache 2010;50:77-84
   PubMed Web of Science ®Google Scholar
• Edvinsson L. Linde Mattias. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
   PubMed Web of Science ®Google Scholar
• Di Trapani G, Mei D, Marra C, Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter 2000;151:145-8
   PubMedGoogle Scholar
• Mathew NT, Rapoport A, Saper J, Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119-28
   PubMed Web of Science ®Google Scholar
• Available from: http://clincaltrials.pharmaceuticals-business-review.com/news/migraine_drug_gabapentin_enacarbil_fails_in_phase_2b_study_gsk_xenoport_100708#
   Google Scholar
• Krusz JC, Albright JP. Lacosamide in the treatment of chronic headache and migraine disorders. 52th annual scientific meeting of the American headache society; Los Angeles; June 2010, PO-104
   Google Scholar
• Available from: www.ucb.com
   Google Scholar
• Pizza V, Busillo V, Agresta A, Elderly patients with migraine: an open-label study on propohylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Villani V, Ciuffoli A, Prosperini L, Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache 2011;51:287-91
   PubMed Web of Science ®Google Scholar
• Smith MI, Read SJ, Chan WN, Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalagia 2000;20:546-53
   PubMed Web of Science ®Google Scholar
• Hadjikhani N, Sanchez Del Rio M, Wu O, Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001;98:4687-92
   PubMed Web of Science ®Google Scholar
• Garza I. Tonabersat: a cortical spreading depression inhibitor as potential pharmacologic prophylaxis in migraine with aura. Curr Neurol Neurosci Rep 2010;10:7-9
   PubMedGoogle Scholar
• Read SJ, Smith MI, Hunter AJ, SB-220453, a potential novel antimigraine compound, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 1999;20:92-9
   Web of Science ®Google Scholar
• Christiansen I, Thomsen LL, Daugaard D, Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalagia 1999;19:660-7
   PubMed Web of Science ®Google Scholar
• Olesen J. Nitric oxide-related drug targets in headache. Neurotherapeutics 2010;7:183-90
   PubMed Web of Science ®Google Scholar
• Høivik HO, Laurijssens BE, Harnisch LO, Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010;30:1458-67
   PubMed Web of Science ®Google Scholar
• Rajanayagam MAS, Li CG, Rand MJ. Differential effects of hydroxocobalamin on NO-mediated relaxations in rat aorta and anococcygeus muscle. Br J Pharmacol 1993;108:3-5
   PubMed Web of Science ®Google Scholar
• van der Kuy PH, Merkus FW, Lohman JJ, Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia 2002;22:513-19
   PubMed Web of Science ®Google Scholar
• Pollack MA, French JH. Hypothesis: glutamic acid in migraine. Headache 1975;15:114-17
   PubMed Web of Science ®Google Scholar
• Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonist in migraine. Expert Opin Investig Drugs 2009;18:789-803
   PubMed Web of Science ®Google Scholar
• Marin JC, Goadsby PJ. Glutamatergic fine tuning with ADX-ø10059: a novel therapeutic approach for migraine? Expert Opin Drugs 2010;19:555-61
   PubMed Web of Science ®Google Scholar
• Kalsbeek A, Palm IF, La Fleur SE, SCN outputs and the hypothalamic balance of life. J Biol Rhythms 2006;21:458-69
   PubMed Web of Science ®Google Scholar
• Alstadhaug KB, Salvesen R, Bekkelund S. 24-hour distribution of migraine. Headache 2008;48:95-100
   PubMed Web of Science ®Google Scholar
• Alstadhaug K, Salvesen R, Bekkelund S. Insomnia and circadian variation of attacks in episodic migraine. Headache 2007;47:1184-8
   PubMed Web of Science ®Google Scholar
• Peres MF, Zukerman E, Da Cunha Tanuri F, Melatonin 3 mg is effective for migraine prevention. Neurology 2004;63:757
   PubMed Web of Science ®Google Scholar
• Wilhelmsen M, Amirian I, Reiter RJ, Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989;165:251-8
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R, Randomised trial of prophylactic daily aspirin in male British doctors. BMJ 1988;296:313-36
   PubMed Web of Science ®Google Scholar
• Buring JE, Peto R, Hennekens CH. Low-dose aspirin for migraine prophylaxis. JAMA 1990;264:1711-13
   PubMed Web of Science ®Google Scholar
• Kirthi V, Derry S, Moore RA, Review: Aspirin reduces acute migraine pain in adults. Cochrane Database Syst Rev 2010(9):CD008041
   Google Scholar
• Ziegler DK, Ellis DJ. Naproxen in prophylaxis of migraine. Arch Neurol 1985;42:582-4
   PubMed Web of Science ®Google Scholar
• Welch KMA, Ellis DJ, Keenan PA. Successful migraine prophylaxis with naproxen sodium. Neurology 1985;35:1304-10
   PubMed Web of Science ®Google Scholar
• Szekely B, Meeryman S, Post G. Prophylactic effects of naproxen sodium on perimenstrual headache: a double blind, placebo-controlled study. Cephalalgia 1989;9:452-3
   Google Scholar
• McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986;83:5731-5
   PubMed Web of Science ®Google Scholar
• Levy D, Burstein R, Strassman AM. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005;58:698-705
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
   PubMed Web of Science ®Google Scholar
• Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997;17:166-74
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23
   PubMed Web of Science ®Google Scholar
• Fernandez-Mayoralas DM, Fernandez-Jaen A, Munoz-Jareno N, Migraine symptoms related to the percutaneous closure of an ostium secundum atrial septal defect: report of four paediatric cases and review of the literature. Cephalalgia 2007;27:550-6
   PubMed Web of Science ®Google Scholar
• Victor TW, Hu X, Campbell JC, Migraine prevalence by age and sex in the United States: a life span study. Cephalalgia 2010;30:1065-72
   PubMed Web of Science ®Google Scholar
• Couturier EG, Bomhof MA, Neven AK, Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-3
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Chee E, Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-23
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008;22:1555-63
   Web of Science ®Google Scholar
• Brandes JL, Poole AC, Kallela M, Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2011;29:1133-48
   Web of Science ®Google Scholar
• Ziaei S, Kazemenajad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Med Sci Monit 2009;15:CR16-19
   PubMed Web of Science ®Google Scholar
• Lance JW, Curran DA. Treatment of chronic tension headache. Lancet 1964;1:1236-9
   PubMed Web of Science ®Google Scholar
• Jackson JL, Shimeall W, Sessums L, Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 2010;341:c5222
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Lee S, Siu M, Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 2009;29:784-91
   PubMed Web of Science ®Google Scholar
• Le Doare K, Akerman S, Holland PR. Occipital afferent activation of second order neurons in the trigeminocervical complex in rat. Neurosci Lett 2006;403:73-7
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Levin M. Greater occipital nerve block for migraine and other headaches. Is it useful? Curr Pain Headache Rep 2007;11:231-5
   PubMedGoogle Scholar
• Claudio A, Caputi MD, Vincenzo F. Therapeutic blockade of greater occipital and supraorbital nerves in migraine patients. Headache 1997;37:174-9
   PubMed Web of Science ®Google Scholar
• Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes – prolonged effects from a single injection. Pain 2006;122:126-9
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573-82
   PubMed Web of Science ®Google Scholar
• Kai-Kai MA, Howe R. Glutamate-immunoreactivity in the trigeminal and dorsal root ganglia, and intreaspinal neurons and fibres in the dorsal horn of the rat. Histochem J 1991;23:171-9
   PubMedGoogle Scholar
• Andreou AP, Goadsby PJ. Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 2009;18:789-803
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. NINDS Clinical Research Center. Chronic Migraine Treatment Trial. Available from: www.ninds.nih.gov/disorders/clinical_trials/NCT00772031.htm
   Google Scholar
• Holroyd KA, Cottrell CK, O`Donnell FJ, Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341:c.4871
   Web of Science ®Google Scholar